Cost-effectiveness of Ivabradine as a Treatment for Systolic Chronic Heart Failure in the United States

被引：0
|
作者：
Kansal, Anuraag R.
Cowie, Martin
Kielhorn, Adrian
Krotneva, Stanimira
Taffazzoli, Ali
Zheng, Ying
Yurgin, Nicole
机构：
来源：
CIRCULATION | 2015年 / 132卷
关键词：
cost effectiveness; systolic chronic heart failure; ivabradine; quality-adjusted life years; hospitalization;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
17655
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial (SHIFT)
    Swedberg, Karl
    Komajda, Michel
    Boehm, Michael
    Borer, Jeffrey S.
    Ford, Ian
    Tavazzi, Luigi
    EUROPEAN JOURNAL OF HEART FAILURE, 2010, 12 (01) : 75 - 81
  • [42] Cost-effectiveness of an inpatient nurse practitioner in heart failure
    Driscoll, Andrea
    Watts, Jennifer J.
    Meagher, Sharon
    Kennedy, Rhoda
    Mar, Ronald
    Johnson, Doug
    Hare, David L.
    Faourque, Omar
    Gao, Lan
    EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING, 2024, 23 (01) : 33 - 41
  • [43] Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective
    Savira, Feby
    Wang, Bing H.
    Kompa, Andrew R.
    Ademi, Zanfina
    Owen, Alice J.
    Zoungas, Sophia
    Tonkin, Andrew
    Liew, Danny
    Zomer, Ella
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2021, 28 (09) : 975 - 982
  • [44] Telemonitoring Versus Usual Care for Elderly Patients With Heart Failure Discharged From the Hospital in the United States: Cost-Effectiveness Analysis
    Jiang, Xinchan
    Yao, Jiaqi
    You, Joyce H. S.
    JMIR MHEALTH AND UHEALTH, 2020, 8 (07):
  • [45] Cost-utility and budget impact of ivabradine in the treatment of heart failure
    Polistena, Barbara
    Maggioni, Aldo Pietro
    Oliva, Fabrizio
    Spandonaro, Federico
    GIORNALE ITALIANO DI CARDIOLOGIA, 2014, 15 (11) : 626 - 633
  • [46] SHIFT trial (Systolic Heart failure treatment with the I-f inhibitor ivabradine Trial) A SHIFT in the treatment of heart failure
    Perrone, Sergio V.
    INSUFICIENCIA CARDIACA, 2010, 5 (03) : 132 - 136
  • [47] Ivabradine therapy effectiveness in patients with chronic heart failure, Functional Class III
    Kanorskiy, S. G.
    Tregubov, V. G.
    Pokrovskiy, V. M.
    CARDIOVASCULAR THERAPY AND PREVENTION, 2011, 10 (02): : 69 - 74
  • [48] Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States
    Thibault, Catherine Saint-Laurent
    Moorjaney, Divya
    Ganz, Michael L.
    Sill, Bruce
    Hede, Shalini
    Yuan, Yong
    Gorsh, Boris
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (07) : 692 - 702
  • [49] Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States
    Bell, CF
    Botteman, MF
    Gao, X
    Weissfeld, JL
    Postma, MJ
    Pashos, CL
    Triulzi, D
    Staginnus, U
    CLINICAL THERAPEUTICS, 2003, 25 (09) : 2464 - 2486
  • [50] Cost-Effectiveness of Baloxavir Marboxil Versus Oseltamivir or no Treatment for the Management of Influenza in the United States
    Kommandantvold, Svenn Alexander
    Chang, Shih-Chen
    Surinach, Andy
    Yau, Vincent
    Best, Jennie H.
    Zaraket, Hassan
    Zhou, Hao
    Frimpter, Jeff
    Zumofen, Marie-Helene Blanchet
    INFECTIOUS DISEASES AND THERAPY, 2024, 13 (09) : 2071 - 2087
12345